Clinical Trials List
2021-10-01 - 2026-12-31
Phase III
Recruiting2
Terminated6
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- MING-YANG WANG 無
- 林柏翰 無
- Wei-Wu Chen 無
- 李宜軒 無
- 羅喬 無
- YEN-SHEN LU 無
- 陳怡君 無
- 郭文宏 無
- 林季宏 無
- 王一中 無
- 蔡立威 無
- 張端瑩 無
- 張允中 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 許志怡 無
- Chun-Yu Liu 無
- Yi-Fang Tsai 無
- 鄭涵方 無
- 許志堅 無
- Jiun-I Lai 無
- 林燕淑 無
- 陳柏方 無
- 陳彥蓁 無
- 邱仁輝 無
- 賴亦貞 無
- Chi-Cheng Huang 無
- 郭懿萱 無
- Ta-Chung Chao 無
- 馮晉榮 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chi-Chang Yu 無
- Wen-Chi Shen 無
- Chun-Hsiu Liu 無
- Wen-Ling Kuo 無
- Mengting Peng 無
- 周旭桓 無
- Chan-Keng Yang 無
- 沈士哲 無
- Yung-Chang Lin 無
- 張潤忠 無
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Chen-Teng Wu 無
- Liang-Chih Liu 無
- 黃至豪 無
- Chih-Jung Chen 無
- Yao-Chung Wu 無
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Zhu-Jun Loh Division of General Surgery
- Wei-Pang Chung Division of Hematology & Oncology
- Yao-Lung Kuo Division of Plastic Surgery
- 黃建璋 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
51 participants
-
Global
900 participants
